比美吉珠单抗治疗中轴型脊柱关节炎3年持续改善患者症状与健康相关生活质量:BE MOBILE研究及其开放标签扩展结果
BE MOBILE 1和2研究纳入494/586(84.3%)随机患者进入开放标签扩展,425/494(86.0%)完成第164周。至第164周,比美吉珠单抗治疗使中轴型脊柱关节炎患者脊柱疼痛、晨僵、身体功能、疲劳、睡眠及健康相关生活质量均较基线持续改善。
要点
- 比美吉珠单抗治疗中轴型脊柱关节炎至3年持续改善脊柱疼痛和晨僵。
- 身体功能、疲劳、睡眠及健康相关生活质量亦持续改善至3年。
- 患者个体水平脊柱疼痛和身体功能改善快速且持续至第164周。
核心结论
- 比美吉珠单抗治疗使中轴型脊柱关节炎患者关键症状和健康相关生活质量快速且持续改善至3年。
研究设计与样本
- BE MOBILE 1(非放射学中轴型脊柱关节炎)和2(放射学中轴型脊柱关节炎)研究包含16周双盲安慰剂对照期和36周维持期,从第16周起所有患者接受比美吉珠单抗160 mg皮下注射每4周一次,第52周符合条件者进入开放标签扩展BE MOVING继续治疗。
- 本文报告总体研究人群至3年脊柱疼痛、晨僵、身体功能、疲劳、睡眠质量和健康相关生活质量的变化,以及脊柱疼痛和身体功能的患者个体数据。
主要发现
- 494/586(84.3%)随机患者进入开放标签扩展,425/494(86.0%)完成第164周。
- 第164周时,患者报告较基线平均改善:总脊柱疼痛-4.3,夜间脊柱疼痛-4.3,晨僵-4.3,身体功能(BASFI)-2.9,疲劳(BASDAI Q1)-3.5、FACIT-Fatigue +9.7,睡眠(MOS-Sleep-R Index II)+10.8,健康相关生活质量(SF-36 PCS +12.3;ASQoL -5.6)。
- 观察到脊柱疼痛和身体功能水平在患者个体水平快速且持续改善至第164周。
临床怎么用
- 对于中轴型脊柱关节炎患者,比美吉珠单抗治疗可长期持续控制脊柱疼痛、晨僵、疲劳等症状并改善身体功能、睡眠和健康相关生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the sustained, long-term efficacy of bimekizumab in improving patient symptoms and health-related quality of life (HRQoL) in axial spondyloarthritis (axSpA) to 3 years. METHODS: Both BE MOBILE 1 (non-radiographic axSpA) and 2 (radiographic axSpA) comprised a 16-week double-blind, placebo-controlled treatment period and a 36-week maintenance period. From week 16, all patients received subcutaneous bimekizumab 160 mg every 4 weeks. At week 52, eligible patients could enter the open-label extension (OLE), BE MOVING and continue bimekizumab treatment. Here, we report pooled results for changes in spinal pain, morning stiffness (mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q5 and Q6), physical function (Bath Ankylosing Spondylitis Functional Index (BASFI)), fatigue (BASDAI Q1 and Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue), sleep quality (Medical Outcomes Study Sleep (MOS-Sleep-R) Index II) and HRQoL (36-Item Short Form Questionnaire (SF-36) Physical Component Summary (PCS)/Mental Component Summary; Ankylosing Spondylitis Quality of Life (ASQoL)) to 3 years in the overall study population; for spinal pain and physical function, patient-level data are also reported. RESULTS: Of the 494/586 (84.3%) randomised patients who entered the OLE, 425/494 (86.0%) completed week 164. At week 164, patients reported mean improvements from baseline in total (-4.3) and nocturnal (-4.3) spinal pain, morning stiffness (-4.3), physical function (BASFI: -2.9), fatigue (BASDAI Q1: -3.5, FACIT-Fatigue: +9.7), sleep (MOS-Sleep-R Index II: +10.8) and HRQoL (SF-36 PCS: +12.3; ASQoL: -5.6). Rapid and sustained patient-level improvements to week 164 in spinal pain and physical function levels were observed. CONCLUSIONS: Bimekizumab treatment led to rapid and sustained improvements in key patient symptoms and HRQoL to 3 years, emphasising its long-term value in controlling symptoms which profoundly affect patients' experience and daily lives. TRIAL REGISTRATION NUMBERS: BE MOBILE 1 (NCT03928704), BE MOBILE 2 (NCT03928743) and BE MOVING (NCT04436640).
引用
- Navarro-Compán V, Kiltz U, Mease PJ, et al. Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension. RMD Open. 2026. PMID: 42128532. doi:10.1136/rmdopen-2025-006670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。